Bayer

Feb 27, 2017

Vulvovaginal Candidiasis (VVC) is an infectious disease, also known as ‘Vaginal thrush’, ‘monilia’, and vulvovaginal candidosis. VVC is usually caused by the yeast species Candida albicans, an infection of vagina associated with itchy rash of the vulva. Common symptoms include itching, soreness or burning discomfort...

Jan 30, 2017

Follicle Stimulating Hormone (FSH) is a glycoprotein secreted by the anterior pituitary, necessary for mammalian reproduction. FSH helps in development and maturation of gonads at puberty, and the hormone acts by binding to FSH receptor. Endometriosis is an extra growth of endometrial tissues in the abdominal cavity...

Oct 06, 2016

Bayer Partners with DelSiTech to Develop Innovative Drug Delivery Technology for Ophthalmology Bayer has partnered with a Finnish drug delivery and drug developmental company,DelSiTechLtd., through a Collaboration and Technology Licence Agreement. The agreement gives Bayer’s compounds a worldwide application of DelS...

Oct 05, 2016

The value of announced mergers and acquisitions (M&A) worldwide fell 27% to $753 billion in the third quarter of 2016, as the companies have become apprehensive in terms of overpaying, which totally prevented the repeat of last year's deal-making frenzy. The Thomson Reuters M&A data is of the view that the f...

Sep 29, 2016

Bayer AG and Evotec AG enter a multi-target research partnership agreement Bayer and Evotec have agreed to develop novel treatments for chronic kidney disease in diabetic patients. According to the agreement, Bayer will have all the rights to select clinical candidates and Evotec’s Cure Nephron target pipeline. It w...

Mar 27, 2015

"We used to think that our fate was in our stars, but now we know that, in large measure, our fate is in our genes, "quotes James Watson. This fate that Watson is talking about is contained in our genes, and deals with a new technique, GENE THERAPY. Gene therapy is an innovative way to fix genetic problem from th...

Nov 05, 2014

Get Market Intelligence of Hemophilia Market with DelveInsight The Haemophilia Market is driven by clotting factor concentrates. Besides hemophilia A and B, and those with von Willebrand disease (VWD), is also sometimes treated with clotting factor. Currently about 20,000 people have hemophilia in the US; about ...